Abstract
Since the current system for the regulation of drugs in the United States was established in 1962, the FDA has steadily increased the scope of its responsibilities and activities, and, concomitantly, the regulatory burden on drug developers. The costs and time that are required for drug development have spiralled upwards. Reform of drug regulation is necessary; it must be fundamental in nature, and it must come from outside the agency through new legislation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
US Food and Drug Administration. About the US Food and Drug Administration. US Food and Drug Administration [online] (cited 20 Jun 2002) 〈http://www.fda.gov/opacom/hpview.html〉 (2002).
US Food and Drug Administration. The Federal Food, Drug and Cosmetic Act. As Amended by the FDA Modernization Act of 1997. US Food and Drug Administration [online] (cited 20 Jun 2002) 〈http://www.fda.gov/opacom/laws/fdcact/fdctoc.htm〉 (1997).
US Food and Drug Administration. The Public Health Service Act. US Food and Drug Administration [online] (cited 20 Jun 2002) 〈http://www.fda.gov/opacom/laws/phsvcact/phsvcact.htm〉 (1999).
Boston Consulting Group. The Contribution of Pharmaceutical Companies: What's at Stake for America (Boston Consulting Group, Boston, 1993).
Peck, C. C. Drug development: improving the process. Food Drug Law J. 52, 163–167 (1997).
Anon. in Pharmaceutical Research and Manufacturers of America, 1999 Industry Profile 33 (PhRMA, Washington DC, 1999).
DiMasi, J. A. et al. Cost of innovation in the pharmaceutical industry. J. Health Econ. 10, 108–142 (1991).
Anon. Tufts Center for the study of drug development pegs cost of a new prescription medicine at $802 million. Tufts Center for the Study of Drug Development [online] (cited Jun 22 2002) 〈http://csdd.tufts.edu/NewsEvents/RecentNews.asp?newsid=6〉 (2001).
Pharmaceutical Research and Manufacturers Association. New Drug Approvals (Pharmaceutical Research and Manufacturers Association, Washington DC, 1998).
Grabowski, H. G. & Vernon, J. M. Returns to R&D on new drug introductions in the 1980s. J. Health Econ. 13, 383–406 (1994).
Miller, H. I. Ill-advised response to a tragedy. Financial Times 11 (14 January 2000).
Fletcher, L. Cubist highlights FDA's antibiotic resistance. Nature Biotechnol. 20, 206–207 (2002).
Anon. The Tufts University Center for the Study of Drug Development, 1996–1997 Annual Report (Tufts University, Boston, 1997).
Testimony of Michael K. Kirk on H.R. 400 before the House Subcommittee on Courts and Intellecutal Property (American Intellectual Property Law Association, Arlington, Virginia, 1997).
US Centers for Disease Control and Prevention. Viral hepititis B. US Centers for Disease Control and Prevention [online] (cited 20 Jun 2002) 〈http://www.cdc.gov/ncidod/diseases/hepatitis/b/index.htm〉 (2002).
Bakke, O. M., Wardell, W. M. & Lasagna, L. Drug discontinuations in the United Kingdom and United States: issues of safety. Clin. Pharmacol. Ther. 35, 559–567 (1984).
Bakke, O. M., Manocchia, M. A., de Abajo, F., Kaitin, K. I. & Lasagna, L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin. Pharmacol. Ther. 58, 108–117 (1995).
US Food and Drug Administration. Improving Public Health Through Human Drugs (US Food and Drug Administration, Washington DC, 2001).
FY 2003 Justification of Estimates for Appropriations Committees. FY 2003 Budget Summary. US Food and Drug Administration [online] (cited 20 Jun 2002) 〈http://www.fda.gov/oc/oms/ofm/budget/2003/BIB2003.pdf〉 (2002).
Goldberg, R. M. Breaking up the FDA's medical information monopoly. Regulation Magazine [online] (cited 20 Jun 2002) 〈http://www.cato.org/pubs/regulation/reg18n2c.html〉 (1995).
Miller, H. I. & Wardell, W. M. in Advancing Medical Innovation: Health, Safety and the Role of Government in the 21st Century (eds Epstein, R. A. et al.) 41–69 (Progress & Freedom Foundation, Washington DC, 1996).
Testimony of Pamela Walker, Mitre-Tek Systems, before the Committee on Labor and Human Resources of the US Senate (Committee on Labor and Human Resources, Washington DC, 1996).
EU Commission Council Directive 93/42/EEC (1993).
Epstein, R. A. in Advancing Medical Innovation: Health, Safety and the Role of Government in the 21st Century (eds Epstein, R. A. et al.) 70–96 (Progress & Freedom Foundation, Washington DC, 1996).
PhRMA. PhRMA Industry Profile 2002 — Chapter 2. Pharmaceutical Research and Manufacturers of America [online] (cited Jun 2002) 〈http://www.phrma.org/publications/publications/profile02/chapter2.pdf〉 (2002).
Biotechnology Industry Organization. Biotechnology Industry Statistics. Biotechnology Industry Organization [online] (cited 20 Jun 2002) 〈http://www.bio.org/er/statistics.asp〉 (2002).
Peltzman, S. Miller's Prescription. Regulation 24, 56–57 (2001).
Bandow, D. The FDA can be hazardous to your health. The Cato Institute [online] (cited Jun 2002) 〈http://www.cato.org/dailys/1-29-97.html〉 (1997).
Anon. Bravo, FDA (Really). Wall Street Journal (3 June 2002).
Miller, H. I. To America's Health: a Proposal to Reform the Food and Drug Administration (Hoover Institution Press, Stanford, California, 2000).
Author information
Authors and Affiliations
Corresponding author
Related links
Related links
DATABASES
Cancer.gov
Medscape DrugInfo
OMIM
FURTHER INFORMATION
Centers for Disease Control and Prevention
European Agency for the Evaluation of Medicinal Products
Johns Hopkins Center for Clinical Trials
Joint Commission on Accreditation of Healthcare Organizations
Occupational Safety and Health Administration
Office of Management and Budget
Rights and permissions
About this article
Cite this article
Miller, H. A proposal for FDA reform. Nat Rev Drug Discov 1, 642–648 (2002). https://doi.org/10.1038/nrd874
Issue Date:
DOI: https://doi.org/10.1038/nrd874
This article is cited by
-
Governmental influences on drug development: striking a better balance
Nature Reviews Drug Discovery (2007)